Battelle, the world’s largest nonprofit research and development
organization, and Canopy Growth Corporation (“Canopy Growth”) (TSX:WEED,
NYSE:CGC), the world’s largest diversified cannabis company, today
announced the completion of multiple fully legal cannabis imports from
Canada to the United States. Battelle and Canopy Growth will work
together to advance knowledge surrounding cannabis in support of medical
research and novel product development.

Canopy Growth and Battelle completed the rigorous federal approval
process required to import cannabis products into the United States and
since October 9th, the organizations have completed four product
transfers to Battelle’s secure research facilities pursuant to United
States Drug Enforcement Agency approvals. For decades, Battelle
scientists have been developing methods for testing a variety of
controlled substances as well as employing analytical chemistry services
for government and private industry.

Notably, product transfers have consisted of a variety of cannabis form
factors, including dried cannabis and Canopy Growth’s precisely dosed
Softgel capsules.

“As more states, including Ohio, approve the use of medical cannabis to
help individuals with certain illnesses, we believe that Battelle will
be able to apply our rigorous and independent research and analysis to
advance knowledge and improve safety in what is essentially uncharted
territory,” said Battelle President and CEO Lou Von Thaer. “We’re
pleased to work with Canopy Growth, a respected global leader in this
emerging market.”

“We’re pleased to begin collaborating with a trusted institution of
Battelle’s reputation,” said Mark Zekulin, President and Co-CEO of
Canopy Growth. “This offers us a unique ability to advance
standardization, intellectual property development and clinical research
that can improve the understanding and legal application of cannabis and
cannabinoids around the globe.”

With a DEA Schedule I Researcher License and product obtained from the
National Institute on Drug Abuse drug supply program, that is fully
legal at the local, state and federal level, Battelle is already
conducting research and development studies involving human subjects and
smoking behavior at an East Coast research center.

Additional areas of research will now begin in earnest to build a robust
knowledge base surrounding Canopy Growth’s suite of cannabis products.

Here's to Future Growth.

About Battelle

Every day, the people of Battelle apply science and technology to
solving what matters most. At major technology centers and national
laboratories around the world, Battelle conducts research and
development, designs and manufactures products, and delivers critical
services for government and commercial customers. Headquartered in
Columbus, Ohio since its founding in 1929, Battelle serves the national
security, health and life sciences, and energy and environmental
industries. For more information, visit www.battelle.org.

About Canopy Growth Corporation

Canopy Growth is a world-leading diversified cannabis and hemp company,
offering distinct brands and curated cannabis varieties in dried, oil
and Softgel capsule forms. From product and process innovation to market
execution, Canopy Growth is driven by a passion for leadership and a
commitment to building a world-class cannabis company one product, site
and country at a time. The Company has operations in 12 countries across
five continents. The Company is proudly dedicated to educating
healthcare practitioners, conducting robust clinical research, and
furthering the public's understanding of cannabis, and through its
partly owned subsidiary, Canopy Health Innovations has devoted millions
of dollars toward cutting edge, commercializable research and IP
development. Through partly owned subsidiary Canopy Rivers Corporation,
the Company is providing resources and investment to new market entrants
and building a portfolio of stable investments in the sector. From our
historic public listing on the Toronto Stock Exchange and New York Stock
Exchange to our continued international expansion, pride in advancing
shareholder value through leadership is engrained in all we do at Canopy
Growth. Canopy Growth has established partnerships with leading sector
names including cannabis icon Snoop Dogg, breeding legends DNA Genetics
and Green House seeds, and Fortune 500 alcohol leader Constellation
Brands, to name but a few. Canopy Growth operates ten licensed cannabis
production sites with over 4.3 million square feet of production
capacity, including over 500,000 square feet of GMP certified production
space. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements

This news release contains “forward-looking statements” within the
meaning of the United States Private Securities Litigation Reform Act of
1995 and “forward-looking information” within the meaning of applicable
Canadian securities legislation. Often, but not always, forward-looking
statements and information can be identified by the use of words such as
“plans”, “expects” or “does not expect”, “is expected”, “estimates”,
“intends”, “anticipates” or “does not anticipate”, or “believes”, or
variations of such words and phrases or state that certain actions,
events or results “may”, “could”, “would”, “might” or “will” be taken,
occur or be achieved. Forward-looking statements or information involve
known and unknown risks, uncertainties and other factors which may cause
the actual results, performance or achievements of Canopy Growth or its
subsidiaries to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements or information contained in this news release. Examples of
such statements include statements with respect to collaborative
research partnerships. Risks, uncertainties and other factors involved
with forward-looking information could cause actual events, results,
performance, prospects and opportunities to differ materially from those
expressed or implied by such forward-looking information, including the
Company’s ability to satisfy provincial sales contracts or provinces
purchasing all cannabis allocated to them, and such risks contained in
the Company’s annual information form dated June 28, 2017 and filed with
Canadian securities regulators available on the Company’s issuer profile
on SEDAR at www.sedar.com.
Although the Company believes that the assumptions and factors used in
preparing the forward-looking information or forward-looking statements
in this news release are reasonable, undue reliance should not be placed
on such information and no assurance can be given that such events will
occur in the disclosed time frames or at all. The forward-looking
information and forward-looking statements included in this news release
are made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
information or forward-looking information to reflect new information,
subsequent events or otherwise unless required by applicable securities
laws.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.